JP2001521009A - 敗血性疾患を治療するための医薬品としてのｔｎｆ拮抗物質の使用 - Google Patents

敗血性疾患を治療するための医薬品としてのｔｎｆ拮抗物質の使用

Info

Publication number: JP2001521009A
Authority: JP; Japan
Prior art keywords: tnf; serum; tnf antagonist; concentration; interleukin
Prior art date: 1997-10-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2000517740A

Other languages

English (en)

Japanese (ja)

Inventor

クッパーハルトムート

カウルマルティン

アイゼルシュタインユルゲン

ダウムロタール

ケンペーニヨアヒム

Original Assignee

クノルアクチエンゲゼルシヤフト

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-10-23

Filing date

1998-10-15

Publication date

2001-11-06

1998-10-15 Application filed by クノルアクチエンゲゼルシヤフト filed Critical クノルアクチエンゲゼルシヤフト

2001-11-06 Publication of JP2001521009A publication Critical patent/JP2001521009A/ja

Status Pending legal-status Critical Current

Links

239000005557 antagonist Substances 0.000 title claims abstract description 24
239000003814 drug Substances 0.000 title claims abstract description 5
201000010099 disease Diseases 0.000 title claims description 10
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 10
102000004889 Interleukin-6 Human genes 0.000 claims abstract description 32
108090001005 Interleukin-6 Proteins 0.000 claims abstract description 32
229940100601 interleukin-6 Drugs 0.000 claims abstract description 29
210000002966 serum Anatomy 0.000 claims abstract description 18
206010040047 Sepsis Diseases 0.000 claims abstract description 16
238000005259 measurement Methods 0.000 claims abstract description 15
238000004519 manufacturing process Methods 0.000 claims abstract description 3
239000012634 fragment Substances 0.000 claims description 6
238000000034 method Methods 0.000 claims description 3
108060008682 Tumor Necrosis Factor Proteins 0.000 description 33
102000003390 tumor necrosis factor Human genes 0.000 description 32
239000004480 active ingredient Substances 0.000 description 7
230000000694 effects Effects 0.000 description 4
238000001802 infusion Methods 0.000 description 4
239000000203 mixture Substances 0.000 description 4
102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
206010040070 Septic Shock Diseases 0.000 description 3
108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 3
229960003227 afelimomab Drugs 0.000 description 3
230000037396 body weight Effects 0.000 description 3
238000000691 measurement method Methods 0.000 description 3
230000036303 septic shock Effects 0.000 description 3
102000003298 tumor necrosis factor receptor Human genes 0.000 description 3
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000001514 detection method Methods 0.000 description 2
230000003902 lesion Effects 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
239000000902 placebo Substances 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
238000011002 quantification Methods 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
208000020084 Bone disease Diseases 0.000 description 1
108010074051 C-Reactive Protein Proteins 0.000 description 1
102100032752 C-reactive protein Human genes 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000003814 Interleukin-10 Human genes 0.000 description 1
108090000174 Interleukin-10 Proteins 0.000 description 1
102000004388 Interleukin-4 Human genes 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
108090001007 Interleukin-8 Proteins 0.000 description 1
102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 1
229940105130 TNF convertase inhibitor Drugs 0.000 description 1
101150033527 TNF gene Proteins 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
102000023732 binding proteins Human genes 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
230000001112 coagulating effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000008094 contradictory effect Effects 0.000 description 1
229930182912 cyclosporin Natural products 0.000 description 1
239000003145 cytotoxic factor Substances 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
229940076144 interleukin-10 Drugs 0.000 description 1
229940028885 interleukin-4 Drugs 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000007119 pathological manifestation Effects 0.000 description 1
230000035778 pathophysiological process Effects 0.000 description 1
238000001050 pharmacotherapy Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
206010040560 shock Diseases 0.000 description 1
230000035939 shock Effects 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229960003433 thalidomide Drugs 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
230000006433 tumor necrosis factor production Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Food Science & Technology (AREA)
Biophysics (AREA)
Biotechnology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Genetics & Genomics (AREA)
Diabetes (AREA)
Mycology (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

JP2000517740A 1997-10-23 1998-10-15 敗血性疾患を治療するための医薬品としてのｔｎｆ拮抗物質の使用 Pending JP2001521009A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE19746868A DE19746868A1 (de)	1997-10-23	1997-10-23	Verwendung von TNF-Antagonisten als Arzneimittel zur Behandlung von septischen Erkrankungen
DE19746868.3		1997-10-23
PCT/EP1998/006545 WO1999021582A2 (de)	1997-10-23	1998-10-15	Verwendung von tnf-antagonisten als arzneimittel zur behandlung von septischen erkrankungen

Publications (1)

Publication Number	Publication Date
JP2001521009A true JP2001521009A (ja)	2001-11-06

Family

ID=7846420

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2000517740A Pending JP2001521009A (ja)	1997-10-23	1998-10-15	敗血性疾患を治療するための医薬品としてのｔｎｆ拮抗物質の使用

Country Status (13)

Country	Link
EP (1)	EP1024831A2 (hu)
JP (1)	JP2001521009A (hu)
KR (1)	KR20010024549A (hu)
CN (1)	CN1163272C (hu)
AU (1)	AU756167B2 (hu)
BR (1)	BR9813114A (hu)
CA (1)	CA2306790A1 (hu)
DE (1)	DE19746868A1 (hu)
HU (1)	HUP0100105A3 (hu)
IL (1)	IL135083A0 (hu)
NO (1)	NO20001894L (hu)
WO (1)	WO1999021582A2 (hu)
ZA (1)	ZA989615B (hu)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2012025749A (ja) *	2010-07-24	2012-02-09	F Hoffmann La Roche Ag	血清に基づく溶液中のインターロイキン６の安定化

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2181297C2 (ru)	2000-06-20	2002-04-20	Эпштейн Олег Ильич	Способ лечения патологического синдрома и лекарственное средство
UA76640C2 (uk) *	2002-08-02	2006-08-15	Олєг Ільіч Епштєйн	Спосіб корекції патологічних імунних реакцій та гомеопатичний лікарський засіб
UA76639C2 (uk)	2002-08-02	2006-08-15	Олєг Ільіч Епштєйн	Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
RU2309732C1 (ru)	2006-03-13	2007-11-10	Олег Ильич Эпштейн	Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
MX2013000543A (es)	2010-07-15	2013-10-28	Oleg Iliich Epshtein	Un metodo para aumentar el efecto de una forma activa potenciada de un anticuerpo.
US8637030B2 (en)	2010-07-15	2014-01-28	Oleg I. Epshtein	Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1990000902A1 (en) *	1988-07-18	1990-02-08	Chiron Corporation	Monoclonal antibodies reactive with cachectin
GB9109645D0 (en) *	1991-05-03	1991-06-26	Celltech Ltd	Recombinant antibodies
NZ278607A (en) *	1994-02-07	1999-05-28	Knoll Ag	Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above

1997
- 1997-10-23 DE DE19746868A patent/DE19746868A1/de not_active Withdrawn
1998
- 1998-10-15 CA CA002306790A patent/CA2306790A1/en not_active Abandoned
- 1998-10-15 KR KR1020007004361A patent/KR20010024549A/ko not_active Ceased
- 1998-10-15 EP EP98955459A patent/EP1024831A2/de not_active Withdrawn
- 1998-10-15 WO PCT/EP1998/006545 patent/WO1999021582A2/de not_active Ceased
- 1998-10-15 JP JP2000517740A patent/JP2001521009A/ja active Pending
- 1998-10-15 HU HU0100105A patent/HUP0100105A3/hu unknown
- 1998-10-15 IL IL13508398A patent/IL135083A0/xx unknown
- 1998-10-15 BR BR9813114-1A patent/BR9813114A/pt not_active IP Right Cessation
- 1998-10-15 AU AU12284/99A patent/AU756167B2/en not_active Withdrawn - After Issue
- 1998-10-15 CN CNB988105144A patent/CN1163272C/zh not_active Expired - Fee Related
- 1998-10-22 ZA ZA9809615A patent/ZA989615B/xx unknown
2000
- 2000-04-12 NO NO20001894A patent/NO20001894L/no not_active Application Discontinuation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2012025749A (ja) *	2010-07-24	2012-02-09	F Hoffmann La Roche Ag	血清に基づく溶液中のインターロイキン６の安定化

Also Published As

Publication number	Publication date
NO20001894D0 (no)	2000-04-12
ZA989615B (en)	2000-04-20
AU756167B2 (en)	2003-01-09
CA2306790A1 (en)	1999-05-06
WO1999021582A3 (de)	1999-07-15
CN1163272C (zh)	2004-08-25
IL135083A0 (en)	2001-05-20
KR20010024549A (ko)	2001-03-26
HUP0100105A3 (en)	2003-08-28
CN1277556A (zh)	2000-12-20
EP1024831A2 (de)	2000-08-09
WO1999021582A2 (de)	1999-05-06
BR9813114A (pt)	2000-08-15
DE19746868A1 (de)	1999-04-29
NO20001894L (no)	2000-04-12
HUP0100105A2 (hu)	2001-05-28
AU1228499A (en)	1999-05-17

Publication	Publication Date	Title
US6235281B1 (en)	2001-05-22	Use of anti-TNF antibodies as drugs for the treatment of disorders with an elevated serum level of interleukin-6
EP1476189A1 (en)	2004-11-17	The use of tnf-alpha antagonist as drugs for the treatment of patients with sepsis and without suffering from total organ failure
US20030012786A1 (en)	2003-01-16	Use of anti-TNF antibodies as drugs in treating septic disorders of anemic patients
AU700819B2 (en)	1999-01-14	Rheumatoid arthritis remedy containing IL-6 antagonist as effective component
RU2607022C2 (ru)	2017-01-10	Способы и композиции для лечения волчанки
CN105705518A (zh)	2016-06-22	用于治疗类风湿性关节炎或作为镇痛药的中和gm-csf的抗体
EP2167038B1 (en)	2018-04-25	Use of taci-ig fusion protein such as atacicept for the manufacture of a medicament for treating lupus erythematosus
JP2001521009A (ja)	2001-11-06	敗血性疾患を治療するための医薬品としてのｔｎｆ拮抗物質の使用
JP2003531822A (ja)	2003-10-28	自己免疫疾患を治療するためのｔｈ−１免疫反応誘導サイトカインの拮抗薬
KR100414505B1 (ko)	2004-03-30	높은혈청수준의인터류킨-6을갖는질환을치료하기위한약물로서의항-tnf항체의용도
MXPA00003355A (en)	2001-05-07	Application of tnf antagonists as medicaments for treating septic diseases
AU5394001A (en)	2001-08-16	The use of anti-TNF antibodies as drugs for the treatment of disorders with an elevated serum level of interleukin-6
CZ20001407A3 (cs)	2001-04-11	Použití TNF antagonistů pro výrobu drog k léčení septických poruch
AU1549599A (en)	1999-04-01	The use of anti-TNF antibodies as drugs for the treatment of disorders with an elevated serum level of the interleukin-6
US20250179131A1 (en)	2025-06-05	Il-18 binding protein (il-18bp) in the treatment of vexas
US20240002519A1 (en)	2024-01-04	Use of il-6 inhibitors for the treatment of acute chest syndrome in patients suffering from sickle cell disease
WO2024155810A1 (en)	2024-07-25	Anti-cd19 binding agents for the treatment and prevention of immune mediated necrotizing myopathy
HK1135027A (en)	2010-05-28	Rheumatoid arthritis remedy containing il-6 antagonist as active ingredient
RU2000112873A (ru)	2002-05-20	Применение антагонистов фактора опухолевого некроза для получения лекарственных средств для лечения септических болезней

JP2001521009A - 敗血性疾患を治療するための医薬品としてのｔｎｆ拮抗物質の使用 - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (3)

Publications (1)

Family

ID=7846420

Family Applications (1)

Country Status (13)

Cited By (1)

Families Citing this family (6)

Family Cites Families (3)

Cited By (1)

Also Published As

Similar Documents